Updates ·
Health notices · Wednesday 7 October
3 notices from the agencies today, in plain words, each with the original linked.
LubriFresh P.M. Nighttime Ointment recalled for sterility concern
FDA · Recall
If you have used Major LubriFresh P.M. Nighttime Ointment, the US Food and Drug Administration has issued a Class II recall notice.
The reason given is lack of assurance of sterility, meaning the product’s cleanliness/sterile quality was not assured.
The notice was published on 2026-09-30, and the ointment was distributed nationwide in the USA.
AvKare lubricant eye drops recalled for sterility concern
FDA · Recall
If you use AvKare carboxymethylcellulose sodium 0.5% lubricant eye drops, the US Food and Drug Administration says there’s a sterility concern. “Sterile” means free from germs that can cause infection.
The notice is for AvKare’s product distributed nationwide in the USA. The FDA published this classification on 2026-09-30.
What changes for you tomorrow: you may need to stop using these specific drops and check whether your bottle matches the recalled product so you’re not using something that may not be reliably germ-free.
No specific next step was included in the notice you provided.
FDA approval for nintedanib capsules
FDA · Approval
If you are an adult with idiopathic pulmonary fibrosis (IPF) or a chronic fibrosing interstitial lung disease (ILD) that has a progressive phenotype, the FDA has approved nintedanib for treatment.
Nintedanib is a kinase inhibitor, a medicine that targets specific cellular signals involved in disease processes. For you, this means a new FDA-approved option is available where treatment was not previously an FDA approval.
The notice does not describe specific next steps for patients beyond the approval itself.